{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-25-059400","form_type":"8-K","ticker":"CLRB","cik":"0001279704","company_name":"Cellectar Biosciences, Inc.","filed_at":"2025-06-13T23:59:59+00:00","discovered_at":"2026-05-14T18:02:47.824036+00:00","generated_at":"2026-05-19T07:38:54.973712+00:00","sec_items":["5.07"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"confidence":"high","headline":"Cellectar shareholders approve reverse stock split, re-elect directors","bullets":["Elected James V. Caruso and Frederick W. Driscoll as Class II directors; Caruso 5,478,892 for, Driscoll 6,207,218 for.","Ratified Deloitte & Touche as independent auditor for FY2025 with 16,651,803 votes for, 219,578 against.","Approved reverse stock split of common stock at ratio 1:10 to 1:30, as determined by Board; 13,464,719 for.","Approved non-binding advisory vote on named executive officer compensation: 5,050,203 for, 2,230,519 against."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-25-059400","json":"https://secwatch.observer/filing/0001104659-25-059400.json","markdown":"https://secwatch.observer/filing/0001104659-25-059400.md","text":"https://secwatch.observer/filing/0001104659-25-059400.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1279704/000110465925059400/0001104659-25-059400-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1279704/000110465925059400/tm2517987d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-19T07:38:54.973712+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}